Flowflex Launches First FDA-Cleared 4-in-1 Home Test for RSV, Flu, and COVID

SAN DIEGO, CA – January 23, 2026 – ACON Laboratories, Inc. today announced the nationwide retail availability of a groundbreaking diagnostic tool that could reshape how families manage seasonal illnesses. The Flowflex® Plus RSV + Flu A/B + COVID 4-in-1 test is the first home test to receive 510(k) clearance from the U.S. Food & Drug Administration (FDA) to simultaneously detect four of the most common respiratory viruses from a single nasal swab.

This over-the-counter rapid antigen test is cleared for use in adults and, significantly, in children as young as six months old. The launch marks a pivotal moment in the expansion of at-home healthcare, empowering consumers to quickly differentiate between Respiratory Syncytial Virus (RSV), Influenza A, Influenza B, and COVID-19 without leaving their homes.

A New Tool for Parental Peace of Mind

For parents and caregivers, the winter months often bring a wave of anxiety as respiratory viruses circulate. A child’s fever, cough, and congestion can trigger a stressful guessing game: Is it a common cold, the flu, COVID-19, or the potentially dangerous RSV? The answer can dictate whether to rush to an urgent care clinic, isolate from vulnerable family members, or manage symptoms at home.

The Flowflex 4-in-1 test aims to eliminate that uncertainty. Its clearance for infants is particularly crucial. According to the U.S. Centers for Disease Control and Prevention (CDC), RSV is the leading cause of hospitalization in young children. The ability to test for it at home provides parents with critical, early information.

“Respiratory symptoms often look the same, but the decisions families need to make can be very different,” said Michael Lynch, Vice President of Sales & Marketing at ACON Laboratories, in a statement. “This test gives people clarity sooner, and in the comfort of their own home.”

The test utilizes a simple nasal swab, with a proprietary swab guard included to ensure safe sample collection from infants and young children by an adult. Results are delivered in approximately 15 minutes, offering a rapid answer that can help guide next steps, from seeking immediate medical advice to implementing isolation protocols to protect others.

Shifting the Landscape of At-Home Diagnostics

The introduction of a multi-pathogen test with full FDA clearance represents a significant evolution in the decentralized healthcare trend that accelerated during the COVID-19 pandemic. While consumers grew accustomed to single-pathogen home tests, this 4-in-1 product signals a new era of more comprehensive at-home diagnostics. The 510(k) clearance, granted on October 27, 2025, is a more rigorous regulatory milestone than the Emergency Use Authorizations (EUAs) that characterized the early pandemic response, indicating the device is as safe and effective as a legally marketed predicate device.

Public health experts see potential benefits in the widespread availability of such tests. Early, rapid identification of infectious diseases can help reduce the burden on crowded emergency rooms and clinics, particularly during peak virus season. According to one infectious disease specialist, at-home triage can empower patients to have more informed conversations with their doctors and can help rationalize the use of healthcare resources. Studies have previously shown that rapid viral diagnostic tests in clinical settings can be associated with reduced antibiotic use and fewer unnecessary procedures.

However, experts also caution that user education is paramount. While the tests are a powerful informational tool, they are not a replacement for professional medical evaluation. The accuracy of any home test can be lower than lab-based PCR tests, and it's critical that users follow instructions carefully and consult a healthcare provider to discuss results and treatment options, especially when a vulnerable individual tests positive or symptoms are severe.

A Strategic Move in a Competitive Market

For ACON Laboratories, this launch is a calculated strategic move to solidify its dominance in the burgeoning home diagnostics market. The company’s Flowflex brand is already America’s #1 home test brand by units sold, according to Circana retail sales data, giving it a powerful platform for launching this next-generation product.

The market for respiratory pathogen testing kits is substantial and growing, with some analysts projecting it to exceed $3.6 billion by 2031. While competitors like BinaxNOW and iHealth offer 3-in-1 tests for COVID-19 and Flu A/B, ACON is the first to integrate RSV detection into an FDA-cleared, over-the-counter format. This key differentiator directly addresses a major concern for the pediatric market, creating a significant competitive advantage.

By developing a more comprehensive panel, ACON is not just adding a feature; it is setting a new standard for what consumers can expect from at-home respiratory tests. The company has also committed to domestic production, with the 4-in-1 test being manufactured at its facility in San Diego, California, ensuring a stable supply chain for the U.S. market.

Accessibility and the Path Forward

The Flowflex Plus RSV + Flu A/B + COVID 4-in-1 test is now available nationwide at major pharmacy chains, including CVS and Walgreens, as well as at retailers like Albertsons. As an over-the-counter product, it does not require a prescription. The test is also eligible for purchase using Flexible Spending Accounts (FSAs), which may help offset the cost for some consumers.

While specific retail pricing is determined by retailers, it is expected to be positioned as a premium but accessible option compared to existing 3-in-1 tests. The question of broader insurance reimbursement for over-the-counter multi-pathogen tests remains a developing area of health policy.

As this technology becomes a common fixture in medicine cabinets, it represents a tangible shift in personal health management. It provides families with an unprecedented level of diagnostic information, enabling quicker, more confident decisions during the most anxious moments of a child's illness and reinforcing the growing role of the empowered patient in modern healthcare.